ADC Therapeutics SA PE Ratio 2019-2022 | ADCT

Current and historical p/e ratio for ADC Therapeutics SA (ADCT) from 2019 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ADC Therapeutics SA PE ratio as of January 26, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ADC Therapeutics SA PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-26 4.72 0.00
2022-09-30 4.82 $-2.16 0.00
2022-06-30 7.95 $-2.44 0.00
2022-03-31 14.69 $-2.55 0.00
2021-12-31 20.20 $-3.00 0.00
2021-09-30 27.16 $-3.28 0.00
2021-06-30 24.35 $-2.64 0.00
2021-03-31 24.41 $-3.70 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.359B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00